Monday, October 3, 2022


Biotechnology News Magazine

Hope Meely appointed Chief Clinical Officer at Slope

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Hope Meely will help clinical trial sponsors and research sites understand how replacing existing manual and paper-driven clinical supply chain processes with the Slope eCSCM platform will reduce clinical trial risk and costs, improve the productivity of clinical trial collaborators, and increase subject retention.

“One of the biggest challenges we face as an industry is ensuring that lab kits, investigational products (IP), devices, ancillary clinical supplies, and biological samples get to the right place, at the right time, in the proper condition,” said Hope Meely.” While we have digitized other aspects of our clinical trial functions with EDCs [electronic data capture], CTMSs [clinical trial management systems], IRTs [interactive response technologies], and other systems, we have not had anything to proactively track and manage our clinical supply chain or reconcile our biological samples backward from biorepository storage, to laboratory, courier, research site, lab kit distributor and manufacturer. The Slope platform gives us all of that.”

“In addition to her decades of experience in various clinical research positions—from data manager to project manager, clinical trial leader, and vice president of clinical operations at companies large and small—she has spent the past 3 years as a Slope customer leading clinical operations,” said Rust Felix, Slope CEO and cofounder. “The depth and breadth of her expertise and knowledge, along with her continued interactions with the industry as a whole, will help inform our company and product direction to meet the critical need for better data-driven clinical supply chain management.”

Hope Meely started her career as a data manager at GlaxoSmithKline. From there, she became a clinical trial leader and senior project manager for companies such as Johnson and Johnson, AstraZeneca, Sanofi, Takeda Pharmaceuticals, and Pharmaceutical Product Development, a clinical research organization. Hope has spent the last three years leading clinical operations for early-phase oncology clinical trials at Prelude Therapeutics. Throughout her career, she has demonstrated passion for adopting innovative technologies that make clinical trial programs and studies more efficient.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine